September 01, 2011 at 12:00 AM
1 minute read
The original version of this story was published on New York Law Journal
Only a single claim is left standing in the latest bellwether trial over whether the bone-density drug Fosamax causes the jaws of users to deteriorate.
Southern District Judge John F. Keenan has granted summary judgment to Merck & Co. Inc. on all but one claim leading up to the start of the Sept. 7 trial in Secrest v. Merck & Co. Inc., 06 Civ. 6292.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
